FUJIFILM Holdings Corporation (TSE: 4901), the Tokyo-based diversified industrial group spanning healthcare, semiconductor materials, business solutions and imaging, reported FY3/2026 consolidated results under U.S. GAAP showing record top- and bottom-line figures. Consolidated revenue rose 5.0% year-on-year to ¥3,356.9 billion — the fourth consecutive all-time high — while operating income increased 6.1% to ¥350.2 billion, the fifth straight record, with an operating margin of 10.4%. Income before income taxes climbed 7.6% to ¥366.6 billion and net income attributable to shareholders rose 6.0% to ¥276.7 billion — the sixth consecutive record. Basic EPS came to ¥229.65 (vs. ¥216.67), ROE was 7.7%, and comprehensive income surged 131.4% to ¥580.7 billion, lifted by a ¥260.2 billion foreign-currency translation gain. Average FX rates were ¥151/USD (vs. ¥152) and ¥175/EUR (vs. ¥164).
Electronics: AI semiconductor materials drive 34% profit jump
The standout segment was Electronics, with revenue up 11.9% to ¥456.1 billion and operating income surging 34.4% to ¥100.9 billion, propelled by robust AI-related semiconductor materials demand. Growth was broad-based across advanced photoresists, NTI developers, copper-wiring CMP slurries, and liquid polyimides for advanced packaging — categories tied directly to the leading-edge logic and advanced-packaging build-out powering generative AI infrastructure. Fujifilm separately announced a ¥5.0 billion equity investment in Rapidus in February 2026 to support Japan's leading-edge logic semiconductor industry.
Imaging: instax crosses 100 million units, GFX ETERNA enters cinema
Imaging delivered revenue of ¥627.0 billion (+15.7%) and operating income of ¥160.0 billion (+14.9%), powered by the instax instant-photo franchise — cumulative shipments now exceeding 100 million units — and new digital cameras including the FUJIFILM GFX100RF, X half, X-E5, and the company's first cinema-oriented camera, the GFX ETERNA 55.
Healthcare and Business Innovation drag, capex skews to Bio CDMO
Healthcare revenue grew 4.9% to ¥1,098.9 billion, but operating income fell 20.3% to ¥63.6 billion, weighed down by softer demand for medical materials in China — even as endoscopes, the SYNAPSE PACS system, in-vitro diagnostics, the Bio CDMO franchise (with new capacity ramping at Denmark, North Carolina, and the UK), and Life Sciences solutions grew. Business Innovation revenue declined 2.0% to ¥1,174.8 billion and operating income fell 14.6% to ¥63.7 billion, as weakness in Office Solutions in Asia-Pacific and Graphic Communication offset stronger DX-related Business Solutions sales in Japan. Capex reached ¥581.9 billion, concentrated in Healthcare (¥444.7 billion) for Bio CDMO expansion; depreciation totaled ¥172.4 billion.
Strategic moves: Bio CDMO scale-up, ETG acquisition, ¥30bn buyback
Capital and strategic actions during the year were unusually active. Fujifilm started up eight 20,000-liter mammalian cell-culture tanks at the new North Carolina Bio CDMO plant, with second-phase investment accelerating; opened an antibody-drug-substance manufacturing building and process development lab in the UK in February 2026; completed the Rapidus equity investment; acquired Turkey-based ETG Global Information Technology Services Inc. in March 2026 (renamed FUJIFILM ETG Global Inc.) to scale ERP/Microsoft Dynamics 365 implementation globally; and resolved a ¥30.0 billion share buyback on March 30, 2026 — completed on April 30, 2026 and followed by cancellation of treasury shares.
Balance sheet, cash flow and dividend
Total assets rose ¥803.9 billion to ¥6,053.8 billion; shareholders' equity stood at ¥3,839.6 billion, with the equity ratio at 63.4%. Operating cash flow totaled ¥410.5 billion; investing activities used ¥554.6 billion primarily for property, plant and equipment, producing negative free cash flow of approximately ¥144 billion. Financing activities provided ¥120.2 billion, mainly from long-term debt issuance, and cash and equivalents ended at ¥170.5 billion. The annual dividend was raised to ¥70.00 per share (¥35.00 interim + ¥35.00 year-end), up from ¥65.00 prior year, with total dividends of ¥84.4 billion and a payout ratio of 30.5%, consistent with the company's policy of around 30% payout complemented by opportunistic buybacks.
FY27 guidance: another record, ¥75 dividend
For FY3/2027, management guides revenue of ¥3,470.0 billion (+3.4%), operating income of ¥365.0 billion (+4.2%), income before income taxes of ¥375.0 billion (+2.3%), and net income attributable to shareholders of ¥280.0 billion (+1.2%), implying EPS of ¥234.19, ROE of 7.8%, and ROIC of 5.6%. The forecast assumes ¥150/USD and ¥175/EUR. The full-year dividend forecast rises to ¥75.00 per share (¥37.50 interim + ¥37.50 year-end), lifting the payout ratio to 32.0%. The outlook does not incorporate potential energy/raw-material impacts from Middle East tensions; as a downside sensitivity, management estimates a quarterly operating-income drag of ¥3.0–4.0 billion if Brent crude sustains around USD 100/barrel. Strategic priorities under VISION2030 center on accelerating Bio CDMO and semiconductor materials, expanding AI-enabled medical imaging and IT services, scaling instax and GFX/X franchises, and improving Business Innovation profitability via structural reform and AI-driven solutions.
| Metric | FY3/2026 | FY3/2025 | YoY |
|---|---|---|---|
| Revenue (¥ billion) | 3,356.9 | 3,195.8 | +5.0% |
| Operating income (¥ billion) | 350.2 | 330.1 | +6.1% |
| Income before taxes (¥ billion) | 366.6 | 340.6 | +7.6% |
| Net income attrib. to shareholders (¥ billion) | 276.7 | 261.0 | +6.0% |
| Basic EPS (¥) | 229.65 | 216.67 | +6.0% |
| Operating margin | 10.4% | 10.3% | +0.1pp |
| ROE | 7.7% | 7.7% | — |
| Equity ratio | 63.4% | — | — |
| Annual dividend (¥) | 70.00 | 65.00 | +7.7% |
JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.